ADA-SCID and your clinical practice - webcast evaluation survey

Moderator: Dr Andrew Gennery
Newcastle University and Great North Children’s Hospital, Newcastle upon Tyne, UK

Dr Claire Booth
UCL Great Ormond Street Institute of Child Health, London, UK

Dr Maria Pia Cicalese
San Raffaele Scientific Institute, Milan, Italy

	Strongly Agree	Agree	Neutral	Disagree	Strongly Disagree
Explain the underlying biology as well as the screening and detection methods for ADA-SCID	Explain the underlying biology as well as the screening and detection methods for ADA-SCID Strongly Agree	Explain the underlying biology as well as the screening and detection methods for ADA-SCID Agree	Explain the underlying biology as well as the screening and detection methods for ADA-SCID Neutral	Explain the underlying biology as well as the screening and detection methods for ADA-SCID Disagree	Explain the underlying biology as well as the screening and detection methods for ADA-SCID Strongly Disagree
Describe and debate the current treatment algorithm for ADA deficiency	Describe and debate the current treatment algorithm for ADA deficiency Strongly Agree	Describe and debate the current treatment algorithm for ADA deficiency Agree	Describe and debate the current treatment algorithm for ADA deficiency Neutral	Describe and debate the current treatment algorithm for ADA deficiency Disagree	Describe and debate the current treatment algorithm for ADA deficiency Strongly Disagree
Summarise the latest advances in gene therapy for ADA-SCID, notably gammaretroviral and lentiviral vector gene therapies, and how these novel treatments can be applied to every day clinical practice	Summarise the latest advances in gene therapy for ADA-SCID, notably gammaretroviral and lentiviral vector gene therapies, and how these novel treatments can be applied to every day clinical practice Strongly Agree	Summarise the latest advances in gene therapy for ADA-SCID, notably gammaretroviral and lentiviral vector gene therapies, and how these novel treatments can be applied to every day clinical practice Agree	Summarise the latest advances in gene therapy for ADA-SCID, notably gammaretroviral and lentiviral vector gene therapies, and how these novel treatments can be applied to every day clinical practice Neutral	Summarise the latest advances in gene therapy for ADA-SCID, notably gammaretroviral and lentiviral vector gene therapies, and how these novel treatments can be applied to every day clinical practice Disagree	Summarise the latest advances in gene therapy for ADA-SCID, notably gammaretroviral and lentiviral vector gene therapies, and how these novel treatments can be applied to every day clinical practice Strongly Disagree

Strongly Agree

Agree

Neutral

Disagree

Strongly Disagree

Explain the underlying biology as well as the screening and detection methods for ADA-SCID

Explain the underlying biology as well as the screening and detection methods for ADA-SCID Strongly Agree

Explain the underlying biology as well as the screening and detection methods for ADA-SCID Agree

Explain the underlying biology as well as the screening and detection methods for ADA-SCID Neutral

Explain the underlying biology as well as the screening and detection methods for ADA-SCID Disagree

Explain the underlying biology as well as the screening and detection methods for ADA-SCID Strongly Disagree

Describe and debate the current treatment algorithm for ADA deficiency

Describe and debate the current treatment algorithm for ADA deficiency Strongly Agree

Describe and debate the current treatment algorithm for ADA deficiency Agree

Describe and debate the current treatment algorithm for ADA deficiency Neutral

Describe and debate the current treatment algorithm for ADA deficiency Disagree

Describe and debate the current treatment algorithm for ADA deficiency Strongly Disagree

Summarise the latest advances in gene therapy for ADA-SCID, notably gammaretroviral and lentiviral vector gene therapies, and how these novel treatments can be applied to every day clinical practice

Summarise the latest advances in gene therapy for ADA-SCID, notably gammaretroviral and lentiviral vector gene therapies, and how these novel treatments can be applied to every day clinical practice Strongly Agree

ADA-SCID and your clinical practice - webcast evaluation survey

Question Title

Question Title

* 1. How well did the webcast fulfil the following learning objectives?

Question Title

* 2. How would you rate the overall quality of the webinar?
10=Excellent, 1=Poor

Question Title

Question Title

Question Title

* 1. How well did the webcast fulfil the following learning objectives?

Question Title

* 2. How would you rate the overall quality of the webinar?10=Excellent, 1=Poor

Question Title

* 2. How would you rate the overall quality of the webinar?
10=Excellent, 1=Poor